


# Fact Sheet


## May 2013

# Cancer, Sepsis, and Atherosclerosis: Targeted Treatment and Diagnosis


### CANCER



### SEPSIS



### ATHEROSCLEROSIS



**SignaBlok therapies and nanotechnologies promote survival in septic mice, suppress tumor growth in animal cancer models, and improve diagnostic imaging of atherosclerosis**

SignaBlok, Inc. is a privately held biotech company based in Massachusetts and focused on the development and commercialization of first-in-class, novel targeted therapies and diagnostics for cancer, sepsis, and atherosclerosis using the company's own intellectual property.

#### SCHOOL Peptide Therapeutics

SignaBlok's model of cell signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, explains for the first time the mechanisms of transmembrane signal transduction mediated by immune receptors. This discovery has led to a novel approach to modulation of receptor signaling and enables the rational design of new, receptor-specific inhibitory peptides (SCHOOL peptides) for therapeutic purposes.

The inhibitory SCHOOL peptides mimic the structures found in nature, employ novel, ligand-independent mechanisms of action, possess unique and beneficial properties and can be used alone or in combination with other therapies. These peptides are non-immunogenic, non-toxic, simple and cheap to manufacture.

#### Integrated Nanosystems for Targeted Delivery

SignaBlok is developing multifunctional nanosystems for targeted delivery of SCHOOL peptides as well as other drugs and/or imaging agents to macrophages with applications in diagnosis and treatment of cancer, sepsis, atherosclerosis, and other serious diseases with unmet clinical needs.

### Company Milestones

- 2009**
  - Company founded
  - Business model developed
  - Notices of patent applications filed
- 2010**
  - First patent applications filed
  - First grant applications submitted
  - Scientific papers published
- 2011**
  - Highlighted by Mass High Tech as a top company to watch
  - Awarded \$150K DARPA contract to test novel approach to sepsis
- 2012**
  - Animal proof-of-concept for sepsis treatment demonstrated
  - Animal proof-of-concept for targeted drug delivery demonstrated
  - Awarded \$220K NIH/NHLBI grant to develop targeted imaging of atherosclerosis
  - Awarded \$220K NIH/NCI grant to test new approach to cancer
  - Partnered with the University of Texas Southwestern Medical Center for novel treatment development for cancer cachexia
- 2013**
  - Animal proof-of-concept for cancer treatment demonstrated
  - Animal proof-of-concept for targeted imaging of atherosclerosis provided

### Contact Us

Alexander Sigalov, PhD  
President, Inventor & Founder

Tel: (203) 505-3807  
sigalov@signablok.com